CommercialCoverageLow impact
08.01.88a, Allogeneic Processed Thymus Tissue-agdc (Rethymic®)
Independence Blue Cross·Endocrinology, Pediatrics, Oncology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
A new commercial policy for Allogeneic Processed Thymus Tissue-agdc (Rethymic®) has been updated, affecting pharmacy coverage for this specialized thymus tissue product. The policy appears to establish coverage criteria or billing guidelines for this therapeutic product.
Action Required
By October 1, 2025: Billing team should review the full policy details at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing procedures for Rethymic® (Allogeneic Processed Thymus Tissue-agdc). Update billing protocols accordingly once full policy content is reviewed.